The Current Role of the sFlt-1/PlGF Ratio and the Uterine–Umbilical–Cerebral Doppler Ultrasound in Predicting and Monitoring Hypertensive Disorders of Pregnancy: An Update with a Review of the Literature

Regarding the hypertensive disorders of pregnancy, pre-eclampsia (PE) remains one of the leading causes of severe and life-threatening maternal and fetal complications. Screening of early-onset PE (<34 weeks of pregnancy), as well as late-onset PE (≥34 weeks), shows poor performance if based solely on clinical features. In recent years, biochemical markers from maternal blood—the pro-angiogenic protein placental growth factor (PlGF) and the antiangiogenic protein soluble FMS-like tyrosine kinase 1 (sFlt-1)—and Doppler velocimetry indices—primarily the mean uterine pulsatility index (PI), but also the uterine resistivity index (RI), the uterine systolic/diastolic ratio (S/D), uterine and umbilical peak systolic velocity (PSV), end-diastolic velocity (EDV), and uterine notching—have all shown improved screening performance. In this review, we summarize the current status of knowledge regarding the role of biochemical markers and Doppler velocimetry indices in early prediction of the onset and severity of PE and other placenta-related disorders, as well as their role in monitoring established PE and facilitating improved obstetrical surveillance of patients categorized as high-risk in order to prevent adverse outcomes. A sFlt-1/PlGF ratio ≤ 33 ruled out early-onset PE with 95% sensitivity and 94% specificity, whereas a sFlt-1/PlGF ≥88 predicted early-onset PE with 88.0% sensitivity and 99.5% specificity. Concerning the condition’s late-onset form, sFlt-1/PlGF ≤ 33 displayed 89.6% sensitivity and 73.1% specificity in ruling out the condition, whereas sFlt-1/PlGF ≥ 110 predicted the condition with 58.2% sensitivity and 95.5% specificity. The cut-off values of the sFlt-1/PlGF ratio for the screening of PE were established in the PROGNOSIS study: a sFlt-1/PlGF ratio equal to or lower than 38 ruled out the onset of PE within one week, regardless of the pregnancy’s gestational age. The negative predictive value in this study was 99.3%. In addition, sFlt-1/PlGF > 38 showed 66.2% sensitivity and 83.1% specificity in predicting the occurrence of PE within 4 weeks. Furthermore, 2018 ISUOG Practice Guidelines stated that a second-trimester mean uterine artery PI ≥ 1.44 increases the risk of later PE development. The implementation of a standard screening procedure based on the sFlt-1/PlGF ratio and uterine Doppler velocimetry may improve early detection of pre-eclampsia and other placenta-related disorders.

[1]  E. Montaguti,et al.  Serum uric acid to creatinine ratio and risk of preeclampsia and adverse pregnancy outcomes , 2023, Journal of Hypertension.

[2]  M. Vatish,et al.  The sFlt1/PlGF ratio predicts faster fetal deterioration in early fetal growth restriction: A historical cohort study , 2023, Acta obstetricia et gynecologica Scandinavica.

[3]  L. Petcu,et al.  Utility of sFtl-1 and Placental Growth Factor Ratio for Adequate Preeclampsia Management , 2023, Healthcare.

[4]  H. Kapaya,et al.  Implementation of Uterine Artery Doppler Scanning: Improving the Care of Women and Babies High Risk for Fetal Growth Restriction , 2023, Journal of pregnancy.

[5]  B. Khan,et al.  Preeclampsia Incidence and Its Maternal and Neonatal Outcomes With Associated Risk Factors , 2022, Cureus.

[6]  M. Candiani,et al.  Reference ranges of uterine artery pulsatility index from first to third trimester based on serial Doppler measurements: longitudinal cohort study , 2022, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[7]  Mengna Li,et al.  Abnormal uterine artery Doppler ultrasound during gestational 21–23 weeks associated with pre‐eclampsia , 2022, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[8]  D. Charnock-Jones,et al.  Increased Placental sFLT1 (Soluble fms-Like Tyrosine Kinase Receptor-1) Drives the Antiangiogenic Profile of Maternal Serum Preceding Preeclampsia but Not Fetal Growth Restriction , 2022, Hypertension.

[9]  M. Vatish,et al.  Clinical utility of sFlt‐1 and PlGF in screening, prediction, diagnosis and monitoring of pre‐eclampsia and fetal growth restriction , 2022, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[10]  Yollyseth Medina,et al.  Assessing the Role of Uric Acid as a Predictor of Preeclampsia , 2022, Frontiers in Physiology.

[11]  Hongbo Zhang,et al.  The clinical value of PlGF and the sFlt1/PlGF ratio in the management of hypertensive pregnancy disorders: a retrospective real-world study in China. , 2022, Clinica chimica acta; international journal of clinical chemistry.

[12]  A. Kurjak,et al.  The Importance of Doppler Analysis of Uterine Circulation in Pregnancy for a Better Understanding of Preeclampsia , 2021, Medical archives.

[13]  L. Magee,et al.  The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. , 2021, Pregnancy hypertension.

[14]  Mengting Zhou,et al.  sFlt-1: a double regulator in angiogenesis-related diseases. , 2021, Current pharmaceutical design.

[15]  V. Phupong,et al.  Prediction of preeclampsia using a combination of serum micro RNA-210 and uterine artery Doppler ultrasound , 2021, Science progress.

[16]  A. Khalil,et al.  Should angiogenic markers be included in diagnostic criteria of superimposed pre‐eclampsia in women with chronic hypertension? , 2021, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[17]  Hae-rin Jeon,et al.  sFlt‐1/PlGF ratio as a predictive and prognostic marker for preeclampsia , 2021, The journal of obstetrics and gynaecology research.

[18]  S. Thangaratinam,et al.  Prognostic indicators of severe disease in late preterm pre-eclampsia to guide decision making on timing of delivery: The PEACOCK study. , 2021, Pregnancy hypertension.

[19]  T. Naicker,et al.  Preeclampsia and HELLP syndrome, the role of the liver , 2021, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[20]  Sarah Heimberger,et al.  Real life outpatient biomarker use in management of hypertensive pregnancies in third trimester in a low resource SeTting: ROBUST study. , 2020, Pregnancy hypertension.

[21]  V. Phupong,et al.  Prediction of preeclampsia using first trimester placental protein 13 and uterine artery Doppler , 2020, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[22]  A. Papageorghiou,et al.  Performance of sFlt-1/PlGF ratio ≥85 for ruling in preeclampsia within 4 weeks. , 2020, American journal of obstetrics and gynecology.

[23]  M. Tuuli,et al.  Third trimester uterine artery Doppler indices as predictors of preeclampsia and neonatal small for gestational age , 2020, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[24]  E. Carreras,et al.  Soluble fms‐like tyrosine kinase to placental growth factor ratio in different stages of early‐onset fetal growth restriction and small for gestational age , 2020, Acta obstetricia et gynecologica Scandinavica.

[25]  M. Rada,et al.  Uterine Artery Doppler Ultrasonography for First Trimester Prediction of Preeclampsia in Individuals at Risk from Low-Resource Settings , 2020, Medicina.

[26]  P. Saha,et al.  Prognostic role of uterine artery Doppler in early- and late-onset preeclampsia with severe features , 2020, Journal of Ultrasound.

[27]  D. Sahota,et al.  First trimester preeclampsia screening and prediction. , 2020, American journal of obstetrics and gynecology.

[28]  F. Figueras,et al.  Added prognostic value of longitudinal changes of angiogenic factors in early‐onset severe pre‐eclampsia: a prospective cohort study , 2020, BJOG : an international journal of obstetrics and gynaecology.

[29]  A. Khalil,et al.  The Prognostic Value of Angiogenic Markers in Twin Pregnancies to Predict Delivery Due to Maternal Complications of Preeclampsia , 2020, Hypertension.

[30]  A. Leaños-Miranda,et al.  Usefulness of the sFlt-1/PlGF (Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor) Ratio in Diagnosis or Misdiagnosis in Women With Clinical Diagnosis of Preeclampsia , 2020, Hypertension.

[31]  Dorairaj Prabhakaran,et al.  2020 International Society of Hypertension Global Hypertension Practice Guidelines. , 2020, Hypertension.

[32]  R. Ratnaparkhi,et al.  Angiogenic factor abnormalities and risk of peripartum complications and prematurity among urban predominantly obese parturients with chronic hypertension. , 2020, Pregnancy hypertension.

[33]  W. Henrich,et al.  Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine: A Real-World Study. , 2020, Hypertension.

[34]  M. Azad,et al.  Diagnostic accuracy of sFlt1/PlGF ratio as a marker for preeclampsia , 2020, BMC Pregnancy and Childbirth.

[35]  B. Grüttner,et al.  Doppler Indices and Notching Assessment of Uterine Artery Between the 19th and 22nd Week of Pregnancy in the Prediction of Pregnancy Outcome , 2019, In Vivo.

[36]  V. Phupong,et al.  Serum SHARP1 and uterine artery Doppler for the prediction of preeclampsia , 2019, Scientific Reports.

[37]  L. Mackillop,et al.  Randomized Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia , 2019, Hypertension.

[38]  K. Tan,et al.  Short-Term Prediction of Adverse Outcomes Using the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio in Asian Women With Suspected Preeclampsia , 2019, Hypertension.

[39]  A. Adeyinka,et al.  Uterine and umbilical artery doppler in women with pre-eclampsia and their pregnancy outcomes , 2019, The Nigerian postgraduate medical journal.

[40]  S. Brennecke,et al.  Soluble fms‐like tyrosine kinase‐1 to placental growth factor ratio: ruling out pre‐eclampsia for up to 4 weeks and value of retesting , 2019, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[41]  K. Nicolaides,et al.  Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35-37 weeks' gestation. , 2019, American journal of obstetrics and gynecology.

[42]  A. Filipek,et al.  [Preeclampsia - a disease of pregnant women]. , 2018, Postepy biochemii.

[43]  A. Papageorghiou,et al.  ISUOG Practice Guidelines: role of ultrasound in screening for and follow‐up of pre‐eclampsia , 2018, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[44]  D. Charnock-Jones,et al.  Screening for fetal growth restriction using ultrasound and the sFLT1/PlGF ratio in nulliparous women: a prospective cohort study. , 2018, The Lancet. Child & adolescent health.

[45]  A. Galindo,et al.  Clinical implementation of the sFlt-1/PlGF ratio to identify preeclampsia and fetal growth restriction: A prospective cohort study. , 2018, Pregnancy hypertension.

[46]  S. Taha,et al.  Combined Doppler ultrasound and platelet indices for prediction of preeclampsia in high-risk pregnancies , 2018, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[47]  L. Magee,et al.  The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. , 2018, Pregnancy hypertension.

[48]  N. Winer,et al.  Evaluation of sFlt-1/PlGF Ratio for Predicting and Improving Clinical Management of Pre-eclampsia: Experience in a Specialized Perinatal Care Center , 2017, Annals of laboratory medicine.

[49]  A. Makris,et al.  Placental growth factor and pre-eclampsia , 2017, Journal of Human Hypertension.

[50]  A. Maged,et al.  Maternal serum homocysteine and uterine artery Doppler as predictors of preeclampsia and poor placentation , 2017, Archives of Gynecology and Obstetrics.

[51]  B. Giraudeau,et al.  First trimester uterine artery Doppler, sFlt-1 and PlGF to predict preeclampsia in a high-risk population , 2017, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[52]  D. Wright,et al.  Comparison of screening for pre‐eclampsia at 31–34 weeks' gestation by sFlt‐1/PlGF ratio and a method combining maternal factors with sFlt‐1 and PlGF , 2017, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[53]  D. Hervás,et al.  sFlt‐1/PlGF for prediction of early‐onset pre‐eclampsia: STEPS (Study of Early Pre‐eclampsia in Spain) , 2016, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[54]  S. Salahuddin,et al.  Sequential plasma angiogenic factors levels in women with suspected preeclampsia. , 2016, American journal of obstetrics and gynecology.

[55]  S. Brennecke,et al.  Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. , 2016, The New England journal of medicine.

[56]  S. Brennecke,et al.  Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice , 2015, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[57]  E. Rogozińska,et al.  Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. , 2014, European journal of obstetrics, gynecology, and reproductive biology.

[58]  N. Shahbazian,et al.  Diagnostic evaluation of uterine artery Doppler sonography for the prediction of adverse pregnancy outcomes , 2014, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[59]  H. Zeisler,et al.  New Gestational Phase–Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia , 2014, Hypertension.

[60]  O. A. Oloyede,et al.  Uterine artery Doppler study in second trimester of pregnancy , 2013, The Pan African medical journal.

[61]  S. Ghosh,et al.  Serum PLGF as a potential biomarker for predicting the onset of preeclampsia , 2012, Archives of Gynecology and Obstetrics.

[62]  E. Gratacós,et al.  Maternal History and Uterine Artery Doppler in the Assessment of Risk for Development of Early- and Late-Onset Preeclampsia and Intrauterine Growth Restriction , 2009, Obstetrics and gynecology international.

[63]  A. Kurjak,et al.  Guidelines for the Doppler Assessment of the Umbilical and Middle Cerebral Arteries in Obstetrics , 2016 .